Emulsomes: An emerging vesicular drug delivery system

Main Article Content

Bhawandeep Gill
Jatinder Singh
Vikas Sharma
S L Hari Kumar


The oral route is the easiest, cost effective, and most vital method for drug administration. Therefore, improvement of dosage forms mainly for the prolonged release purpose has been a challenge for scientists. Vesicular drug delivery
systems are developed with a purpose to overcome problems coupled with the drugs such a poor bioavailability, protection from harsh gastric environment, and from gastric enzymes, which degrade the drug.Vesicular drug delivery systems such as liposomes, emulsions, niosomes, proniosomes, solid lipid-nano particles, ethosomes, nanoparticles, and pharmacosomes, etc have gained much attention, but emulsomes have rouse as system, which bypasses many disadvantages associated with other systems, developed as novel lipoidal vesicular system with internal solid fat core surrounded by phospholipid bilayer. This technology is designed to act as vehicle for poorly soluble drugs.The drug is enclosed in the emulsomes and provide prolong existence of drug in systemic circulation. Furthermore, emulsomal-based formulations of genetic drugs such as antisense
oligonucleotides and plasmids for gene therapy that have clear potential for systemic utility are increasingly available. This review addresses the concept of emulsomal drug delivery system, summarizes the success of emulsomes for the delivery of small molecules, and special attention has been paid to its formulation design, advantages, biopharmaceutical aspects,
stability aspects, and various aspects related to drug delivery including future aspects.


Download data is not yet available.

Article Details

How to Cite
Gill, B., Singh, J., Sharma, V., & Kumar, S. L. H. (2014). Emulsomes: An emerging vesicular drug delivery system. Asian Journal of Pharmaceutics (AJP), 6(2). https://doi.org/10.22377/ajp.v6i2.60


Arien A, Dupuy B. Encapsulation of calcitonin in liposomes depends in

the vesicle preparation method. J Microencapsul 1997;14:753-60.

Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions

across the lamellae of swollen phospholipids. J Mol Biol 1965;13:238-52.

Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carriers:Dermal and transdermal drug delivery. J Control Release 1994;30:1-15.

Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev 1997;25:103-28

Kim S. Liposomes as carriers of cancer chemotherapy and future aspects.Drugs 1993;46:618-38.

Zhu L, Huo Z, Wang L, Tong X, Xiao Y, Ni K. Targeted delivery

of methotrexate to skeletal muscular tissue by thermosensitive

magnetoliposomes. Int J Pharm 2009;370:136-43.

Barber R, Shek P. Liposomes as a topical ocular drug delivery system.

In: Rolland A, editor. Pharmaceutical Particulate Carriers. New York:

Marcel Dekker; 1993. p. 1-20.

Singh SK, Rajera R, Nagpal K, Mishra DN. Niosomes: A controlled and

novel drug delivery system. Biol Pharm Bull 2011;34:945-53.

Vyas SP, Subhedar R, Jain S. Development and characterization of

emulsomes for sustained and targeted delivery of an antiviral agent

to liver. J Pharm Pharmacol 2006;58:321-6.

Paliwal R, Paliwal SR, Mishra N, Mehta A, Vyas SP. Engineered

chylomicron mimicking carrier emulsome for lymph targeted oral

delivery of methotrexat. Int J Pharm 2009;380:181-8.

VanCott TC, Kaminski RW, Mascola JR, Kalyanaraman VS, Wassef NM,

Alving CR, et al. HIV-1 neutralizing antibodies in the genital and

respiratory tracts of mice intranasally immunized with oligomeric

gp160. J Immunol 1998;160:2000-12.

Schwarz C, Mehnert W, Lucks JS, Muller RH. Solid lipid nanoparticles

(SLNs) for controlled drug delivery: I. Production, characterization and

sterilization. J Control Release 1994;30:83-96.

Vyas SP, Gupta S, Dube A. Antileishmanial efficacy of amphotericin b

bearing emulsomes against experimental visceral leishmaniasis. J Drug

Target 2007;15:437-44.

Gupta S, Vyas SP. Development and characterization of Amphotericin

B bearing emulsomes for passive and active macrophage targeting.

J Drug Target 2006;15:206-17.

Weinstock PH, Bisgaier CL, Hayek T, Aalto-Setala K, Sehayek E,

Sheiffele P, et al. Decreased HDL choesterol levels but normal lipid

absorption, growth and feeding behavior in apolipoprotein a-iv

knockout mice. J Lipid Res 1997;38:1782-94.

Ziv E, Bendayan M. Intestinal absorption of peptides through the

enterocytes. Microsc Res Tech 2000;49:346-52.

Raybould HE. Nutrient tasting and signaling mechanisms in the gut. I.

Sensing of lipid by the intestinal mucosa. Am J Physiol 1999;277:G751-5.

Welling PG. Influence of food and diet on gastrointestinal drug

absorption: A review. J Pharmacokinet Biopharm 1977;5:292-334.

Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based

formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev

Drug Discov 2007;6:231-48.

Wagnera D, Spahn-Langguthb H, Hanafyb A, Koggela A, Langgutha P.

Intestinal drug efflux: Formulation and food effects. Adv Drug Deliv

Rev 2001;50(supply 1):S13-31.

Brocks DR, Betageri GV. Enhanced oral absorption of halofantrine

enantiomers after encapsulation in a proliposomal formulation. J Pharm

Pharmacol 2002;54:1049-53.

Hauss DJ. Oral lipid based formulations. Adv Drug Deliv Rev

;59:667- 76.

Hofmann AF, Borgstrom B. The intraluminal phase of fat digestion

in man: The lipid content of the micellar and oil phases of intestinal

content obtained during fat digestion and absorption. J Clin Invest


Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS)

for improved oral delivery of lipophilic drugs. Biomed Pharmacother


Pouton CW. Formulation of poorly water-soluble drugs for oral

administration: Physicochemical and physiological issues and the lipid

formulation classification system. Eur J Pharm Sci 2006;29:278-87.

Chambin O, Jannin V. Interest of multifunctional lipid excipients: Case

of Gelucire 44/14. Drug Dev Ind Pharm 2005;31:527-34.

Gupta KS, Nappinnai M, Gupta VRM. Formulation and evaluation of

topical meloxicam niosomal gel. Int J Biopharm 2010;1:7-13.

Kulthe VV, Chaudhari PD. Solubility enhancement of etoricoxib by

solid dispersions prepared by spray drying technique. Int J Pharm Res


Vilhemsen T, Eliasen H, Schaefer T. Effect of a melt agglomeration

process on agglomerates containing solid dispersions. Int J Pharma


Solid Fat Nanoemulsions As Drug Delivery Vehicles-Patent 5576016.

Available from: http://www.docstoc.com/docs/48874511/Solid-Fat-


Banerjee A, Roychoudhury J, Ali N. Stearylamine-bearing cationic

liposomes kill leishmania parasites through surface exposed

negatively charged phosphatidylserine. J Antimicrob Chemother


Sudhamani T, Priyadarisini N, Radhakrishna. Proniosomes–A promising

drug carriers. Int J PharmTech Res 2010;2:1446-54.

Sek L, Porter CJH, Charman WN. Characterisation and quantification of

medium chain and long chain triglycerides and their in-vitro digestion

products, by HPTLC coupled with in situ densitometric analysis. J Pharm

Biomed Anal 2001;25:651-61.

Mujoriya R, Bodla RB, Dhamande K, Singh D, Patle L. Niosomal drug

delivery system: The magic bullet. JAPS 2011;1:20-3.

Ruckmani K, Sankar V. Formulation and optimization of zidovudine

niosomes. AAPS PharmSciTech 2010;11:1119-27.

Venkatesan N, Vyas SP. Polysaccharide coated liposomes for oral

immunization: Development and characterization. Int J Pharm


Hofland HEJ, Boustra JA, Verhoef JC, Buckton G, Chowdry BZ, Ponec M,

et al. Safety aspects of non-ionic surfactant vesicles a toxicity study

related to the physicochemical characteristics of non-ionic surfactants.

J Pharm Pharmacol 1992;44:287-94.

Hood E, Gonzalez M, Plaas A, Strom J, VanAuker M. Immunotargeting

of nonionic surfactant vesicles to inflammation. Int J Pharm

;339:222- 30.

Azeem A, Anwer MK, Talegaonkar S. Niosomes in sustained and targeted

drug delivery: Some recent advances. J Drug Target 2009;17:671-89.

Barry BW. Novel mechanisms and devices to enable successful

transdermal drug delivery. Eur J Pharm Sci 2001;14:101-14.

Devaraj GN, Parakh SR, Devraj R, Apte SS, Rao BR, Rambhau D. Release

studies on niosomes containing fatty alcohols as bilayer stabilizers

instead of cholesterol. J Colloid Interface Sci 2002;251:360-5.

Kirby C, Clarke J, Gregoriadis G. Effect of cholesterol content of small

unilamellar liposomes on their stability in vivo and in vitro. Biochem J


Harasym TO, Cullis PR, Bally MB. Intratumor distribution of

doxorubicin following I.V. Administration of drug encapsulated in

egg phosphatidylcholine cholesterol liposomes. Cancer Chemother

Pharmacol 1997;40:309-17.

Harder T, Simons K. Caveolae, digs, and the dynamics of sphingo-lipid

cholesterol microdomains. Curr Opin Cell Biol 1997;9:534-42.

Papahadjopoulos D, Cowden M, Kimelberg H. Role of cholesterol

in membranes, effects on phospholipidprotein interactions,

membrane permeability and enzymatic activity. Biochim Biophys

Acta 1973;330:8-26.

Snjezana S. PLGA nanoparticles prepared by nanoprecipitation: Drug

loading and release studies of water soluble drug. J Control Release


Ibrahim MMA, Sammour OA, Hammad MA, Megrab NA. In vitro

evaluation of proniosomes gel as A drug carrier for flurbiprofen. AAPS

PharmSciTech 2008;9:782-90.

Fang JY, Hong CT, Chiu WT, Wang YY. Effect of liposomes and niosomes

on skin permeation of enoxacin. Int J Pharm 2001;219:61-72.

Dipali SR, Kulkarni SB, Betageri GV. Comparative study of separation of

non-encapsulated drug from unilamellar liposomes by various methods.

J Pharm Pharmacol 1996;48:1112-5.

Ljeoma FU, Vyas SP. Non-ionic surfactant based vesicles in drug delivery.

Int J Pharm 1998;172:33-70.

Szoka F, Papahadjopoulos D. Procedure for preparation of liposomes

with large internal aqueous space and high capture by reverse-phase

evaporation. Proc Natl Acad Sci U S A 1978;75:4194-8.

Vemuri S, Rhodes CT. Preparation and characterization of liposomes as

therapeutic delivery systems: A review. Pharm Acta Helv 1995;70:95-111.

Balasubramaniam A, Kumar VA, Palliai KS. Formulation and in-vivo

evaluation of niosomes encapsulated daunorubicin hydrochloride.

Drug Dev Ind Pharm 2002;28:1181-93.

Hope MJ, Bally MB, Webb G, Cullis P. Production of large unilamellar

vesicles by rapid extrusion procedure: Characterization of size

distribution, trapped volume, and ability to maintain a membrane

potential. Biochim Biophys Acta 1985;812:55-65.

Batzri S, Korn ED. Single bilayer liposomes prepared without sonication.

Biochim Biophys Acta 1973;298:1015-9.

Fry DW, White JC, Goldman ID. Rapid separation of low molecular

weight solutes from liposomes without dilution. Anal Biochem


Dayan N, Touitou E. Carriers for skin delivery of Trihexyphenidyl HCl:

Ethosomes vs. Liposomes. Biomaterials 2000;21:1879-85.

Sugarman SM, Zou YY, Wasan K, Poirot K, Kumi R, Reddy S, et al. Lipid-

complexed camptothecin: Formulation and initial biodistribution and

anti-tumor activity studies. Cancer Chemother Pharmacol 1996;37:531-8.

Vemuri S, Yu C, Wangsatorntanakun V, Roosdorp N. Large-scale

production of liposomes by Microfluidizer. Drug Dev Ind Pharm


Kremer JM, Esker MW, Pathmamanoharan C, Wiersema PH. Vesicles

of variable diameter prepared by a modified injection method.

Biochemistry 1977;16:3932-5.

Lundberg BB. Biologically active comptothecin derivatives for

incorporation into liposomes bilayers and lipid emulsion. Anticancer

Drug Des 1988;13:453-61.

Pons M, Foradada M, Estelrich J. Liposomes obtained by the ethanol

injection method. Int J Pharm 1993;95:51-6.

Stano P, Bufali S, Pisano C, Bucci F, Barbarino M, Santaniello M, et al. Novel

camptothecin analogue (Gimatecan)-containing liposomes prepared by

the ethanol injection method. J Liposome Res 2004;14:87- 09.

Campbell MJ. Lipofection reagents prepared by simple ethanol injection

technique. Biotechniques 1995;18:1027-32.

Domazou A, Luisi PL. Size distribution of spontaneously formed

liposomes by the alcohol injection method. J Liposome Res

;12:205- 20.

Kagawa Y, Racker E. Partial resolution of the enzymes catalyzing

oxidative phosphorylation. J Biol Chem 1971;246:5477-87.

Milsmann MHW, Schwendner RA, Weder H. The preparation of large

single bilayer liposomes by a fast and controlled dialysis. Biochim

Biophys Acta 1978;512:147-55.

Enoch HAG. Strittmatter P. Formation and properties of 1000 A

diameter, single-bilayer phospholipid vesicles. Proc Natl Acad Sci U S A


Porter CJH, Charman WN. Uptake of drugs into the intestinal lymphatics

after oral administration. Adv Drug Deliv Rev 1997;25:71-89.

Dintaman JM, Silverman JA. Inhibition of P-glycoprotein by Dalpha-

tocopheryl Polyethylene Glycol 1000 Succinate (TPGS). Pharm Res


Nerurkar MM, Burton PS, Borchardt RT. The use of Surfactants to

Enhance the Permeability of Peptides Through Caco-2 Cells by Inhibition

of An Apically Polarized Efflux System. Pharm Res 1996;3:528-34.

Aungst BJ. Intestinal permeation enhancers. J Pharm Sci 2000;


Muranishi S. Absorption enhancers. Crit Rev Ther Drug Carrier Syst


Erion MD, Van Poelje PD, Mackenna DA, Colby TJ, Montag AC,

Fujitaki JM, et al. Liver-targeted drug delivery using hepdirect prodrugs.

J Pharmacol Exp Ther 2005;312:554-60.

Banerjee G, Nandi G, Mahato SB, Pakrashi A, Basu MK. Drug delivery

system: Targeting of pentamidines to specific sites using sugar-grafted

liposomes. J Antimicrob Chemother 1996;38:145-50.

Moghbel A, Zand Moghaddam A, Rezaee S, Pedram M. High performance

liquid chromatography determination of methotrexate in plasma. Iran

J Pharm Res 2003;2:149-52.

Goldsmith DR, Perry CM. Amphotericin B lipid complex: In visceral

leishmaniasis. Drugs 2004;64:1905-11.

Kole L, Sakar K, Mahato SB, Das PK. Neoglycoprotein conjugated

liposomes as macrophage specific drug carrier in the therapy of

leishmaniasis. Biochem Biophys Res Commun 1994;200:351-8.

Sanchez-Brunete JA, Dea MA, Rama S, Bolas F, Alunda JM, Raposo R, et al.

Treatment of experimental visceral leishmaniasis with amphotericin

B in stable albumin microspheres. Antimicrob Agents Chemother


Lowell GH, Kaminski RW, VanCott TC, Slike B, Kersey K, Zawoznik E,

et al. Proteosomes, emulsomes, and cholera Toxin B Improve nasal

immunogenicity of human immunodeficiency virus Gp160 in mice:

Induction of serum, intestinal, vaginal, and Lung IgA and IgG. J Infect

Dis 1997;175:292-301.

Most read articles by the same author(s)